Epigenomics AG

EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Not for distribution in the United States. Epigenomics AG Places Maximum Number of New Shares in Capital Increase ...

@@start.t1@@--------------------------------------------------------------------------------   ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro   adhoc with the aim of a Europe-wide distribution. The issuer is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

Company Information/Molecular diagnostics


Berlin, Germany, March 30, 2010 - Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A0BVT96) today successfully completed the placement of 14,697,361 new ordinary bearer shares within a rights offering representing the entire authorized capital available. The new shares were placed at the subscription price of EUR 2.25 per new share resulting in gross proceeds of about EUR 33.1 million. The rights offering started on March 15, 2010 and ended on March 29, 2010.

The subscription rate in the  transaction  was  46.2%  equalling   6,789,613  new shares. The remaining  7,907,748  unsubscribed  new   shares  were  sold  at  the subscription price to retail investors as part of a public offering  in  Germany and Austria, as well as to   selected  institutional  investors  in  Germany  and abroad.  This   public  offering  was  significantly    oversubscribed,    enabling Epigenomics AG to place the entire number of new shares. A sizeable   portion  of the unsubscribed new shares were placed with funds managed  by  Abingworth  LLP, London, United Kingdom, that  in   addition  to  exercising  pre-emptive  rights, increased their stake in Epigenomics  AG  to  become  the  largest  shareholders after the capital increase.

ICF Kursmakler AG (Frankfurt, Germany) acted  as  sole  lead  manager and  sole underwriter.

The registration  of  the  implementation  of  the  capital  increase with  the commercial register (Handelsregister) and the admission of the  new  shares  to the regulated market (regulierter  Markt),   Prime  Standard,  of  the  Frankfurt Stock Exchange is expected on or around March  31,  2010.  Trading  in  the  new shares is expected to begin on or around April 1, 2010.

With the registration of the implementation of the capital  increase the  total issued share capital of Epigenomics increases  from  EUR   29,394,724.00  to  EUR 44,092,085.00.

Epigenomics AG intends to use the net proceeds from the offering to finance its current operations and to build and strengthen the marketing, sales, and distribution capacities for its products, to support ongoing and new product development for its business in cancer screening, diagnosis, disease progression and recurrence monitoring, and assessment of disease prognosis and in this areas in particular the funding of further R&D, clinical trials, regulatory approvals and market introduction of its products that are currently in its product pipeline as well as enhancing and strengthening capabilities related to regulatory affairs and clinical trials, further improvement of the DNA methylation technology, additional in-licensing agreements and strengthening its intellectual property portfolio, as well as for general corporate purposes.


This publication is not an offer of any securities for sale  or  a   solicitation of an offer to purchase any securities.

This document is not an offer of securities for sale or  a   solicitation  of  an offer to purchase securities in the United States. The shares of Epigenomics  AG (the "Shares") have not been registered under the U.S. Securities Act  of  1933, as amended (the "Securities Act") and may not be offered or sold in  the  United States unless registered under the Securities Act or pursuant  to  an exemption from such registration. There will be no public offering of the  Shares  in  the United States and the Shares will not be registered under the Securities Act.

This document is only being distributed to and is only directed at   (i)  persons who are outside the United Kingdom or (ii) to investment professionals  falling within Article 19(5) of the Financial Services and Markets Act  2000  (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and  other persons to  whom  it   may  lawfully  be  communicated,  falling  within  Article 49(2)(a) to (d) of the Order (all such persons together  being  referred  to   as "relevant persons"). The Shares are  only  available  to,  and   any  invitation, offer or agreement to subscribe, purchase or otherwise acquire  such  securities will be engaged in only  with,   relevant  persons.  Any  person  who  is  not  a relevant person should not act or rely on this document or any of its contents.

This communication expressly  or  implicitly  contains  certain   forward-looking statements concerning Epigenomics AG and its business. Such  statements  involve certain known and unknown risks, uncertainties and  other  factors  which  could cause the actual results, financial condition, performance  or  achievements  of Epigenomics AG to be materially different from any future  results,   performance or  achievements  expressed  or  implied  by  such   forward-looking  statements. Epigenomics AG is providing this communication as of  this  date  and  does  not undertake to update any forward-looking statements contained herein as a  result of new information, future events or otherwise.

The offer in Germany and Austria was made exclusively by means  of   and  on  the basis of a prospectus published and available free of charge at  Epigenomics  AG (fax number +49 30 24345 555) and ICF Kursmakler AG (fax number  +49  69  92877- 222).


Epigenomics AG Dr. Achim Plum Senior VP Corporate Development Kleine Präsidentenstr. 1 10178 Berlin Germany +49 30 24345 368 (phone) +49 30 24345 555 (fax) achim.plum@epigenomics.com

@@start.t2@@end of announcement                                                 euro adhoc

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368

Branche: Biotechnology
ISIN:      DE000A0BVT96
WKN:        A0BVT9
Index:    Prime All Share, Technology All Share
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Hamburg / free trade
              Stuttgart / free trade
              Düsseldorf / free trade
              München / free trade

Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: